• Title of article

    Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting

  • Author/Authors

    Robert A. Henderson، نويسنده , , Stuart J. Pocock، نويسنده , , Stephen J Sharp، نويسنده , , Kiran Nanchahal، نويسنده , , Mark J. Sculpher، نويسنده , , Martin J Buxton، نويسنده , , John R. Hampton، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 1998
  • Pages
    7
  • From page
    1419
  • To page
    1425
  • Abstract
    Background Percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass grafting (CABG) are both effective intervention strategies for patients with coronary heart disease. We report comparative long-term clinical and health-service cost findings for these interventions in the first Randomised Intervention Treatment of Angina (RITA-1) trial. Methods 1011 patients with coronary heart disease (45% single-vessel, 55% multivessel) were randomly assigned initial treatment strategies of PTCA or CABG. Information on clinical events, subsequent intervention, symptomatic status, exercise testing, and use of health-care resources is available for a median 6·5 years of follow-up. Analyses were by intention to treat. Findings The predefined primary endpoint of death or nonfatal myocardial infarction occurred in 87 (17%) PTCA-group patients and 80 (16%) CABG-group patients (p=0·64). Similarly, there was no significant treatment difference in deaths alone (39 PTCA, 45 CABG), of which 46% were cardiac related. In both groups, the risk of cardiac death or myocardial infarction was more than five times higher in the first year than in subsequent years of follow-up. 26% of patients assigned PTCA subsequently also had CABG, and a further 19% required additional nonrandomised PTCA. Most of these reinterventions occurred within a year of randomisation, and from 3 years onwards the reintervention rate averaged 4% per year. In the CABG group the reintervention rate averaged 2% per year. The prevalence of angina was consistently higher in the PTCA group, with an absolute average 10% excess compared with the CABG group (p<0·001). Total health-service costs over 5 years showed no significant difference between initial strategies of PTCA and CABG (mean difference £426 [95% CI–£383 to £1235]; p=0·30). The clinical and cost comparisons showed similar patterns for patients with single-vessel and multivessel disease. Interpretation Initial strategies of PTCA and CABG led to similar long-term results in terms of survival and avoidance of myocardial infarction and to similar long-term healthcare costs. Choice of approach, therefore, rests on weighing the more invasive nature of CABG against the greater risk of recurrent angina and reintervention over many years after PTCA.
  • Journal title
    The Lancet
  • Serial Year
    1998
  • Journal title
    The Lancet
  • Record number

    578697